Evidence map›Paper›PMID 41373615›Full record

ArticleInternational journal of molecular sciences2025

Role of ERβ in Triple-Negative Breast Cancer Associated with p53 and Androgen Receptor.

Kei Ito, Naoko Honma, Hideaki Ogata, Akimitsu Yamada, Mika Miyashita, Tomio Arai, Eiichi Sasaki, Kazutoshi Shibuya, Tetuo Mikami, Masataka Sawaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kei ItoDepartment of Pathology, Toho University Faculty of Medicine, Omori-Nishi 5-21-16, Ota-ku, Tokyo 143-8540, Japan.ORCID 0000-0001-7967-3563
Naoko HonmaDepartment of Surgical Pathology, Toho University Faculty of Medicine, Omori-Nishi 5-21-16, Ota-ku, Tokyo 143-8540, Japan.
Hideaki OgataDepartment of Breast and Endocrine Surgery, Toho University Omori Medical Center, Omori-Nishi 6-11-1, Ota-ku, Tokyo 143-8541, Japan.
Akimitsu YamadaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama 236-0004, Japan.
Mika MiyashitaPalliative Care Nursing, Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Shogoin-Kawahara-cho 53, Sakyo-ku, Kyoto 606-8507, Japan.
Tomio AraiDepartment of Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan.
Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Kanokoden 1-1, Chikusa-ku, Nagoya 464-8681, Japan.ORCID 0000-0002-6385-8341
Kazutoshi ShibuyaDepartment of Surgical Pathology, Toho University Faculty of Medicine, Omori-Nishi 5-21-16, Ota-ku, Tokyo 143-8540, Japan.
Tetuo MikamiDepartment of Pathology, Toho University Faculty of Medicine, Omori-Nishi 5-21-16, Ota-ku, Tokyo 143-8540, Japan.
Masataka SawakiDepartment of Breast Oncology, Nagoya Medical Center, National Hospital Organization 4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001, Japan.

Funding

Ministry of Education, Culture, Sports, Science and Technology 16K08660The Japanese Breast Cancer Society Grant-in-Aid for Scientific Research
6 · The paper itself

Abstract

In triple-negative breast cancer (TNBC), the clinicopathological significance of the expression of a second estrogen receptor, ERβ, remains unclear. Further, although the clinicopathological significance of mutant p53 and androgen receptor (AR) has been investigated in TNBC, they have not been established as therapeutic targets. Experimental studies reported the importance of cross-talk between ERβ and p53 or AR in TNBC. In this study, we immunohistochemically examined ERβ expression in surgical specimens of TNBC obtained from postmenopausal patients who underwent surgery without neoadjuvant therapy and investigated the relationship between ERβ expression and various clinicopathological factors, including clinical outcome, while also considering p53 and AR. No significant difference in clinical outcome was noted according to the ERβ status alone (

Indexed as

Estrogen Receptor betaReceptors, AndrogenTriple Negative Breast NeoplasmsTumor Suppressor Protein p53AgedFemaleHumansMiddle AgedPrognosisAR protein, humanEstrogen Receptor betaReceptors, AndrogenTP53 protein, humanTumor Suppressor Protein p53androgen receptorclinical outcomeestrogen receptor-βp53triple-negative breast cancer

Identifiers

PMID41373615
PMCPMC12692495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.